Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 13/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706654 | 0.92 | PDE4B (0.52) | SLC34A1BRD4CREBBPPDE4BACHE | |
| SCHEMBL3032602 | 0.91 | PDE4B (0.44) | SLC34A1BRD4CREBBPPDE4BACHE | |
| SCHEMBL4707585 | 0.89 | PDE4B (0.55) | SLC34A1PDE4BACHEBACE1MCHR1 | |
| SCHEMBL4708006 | 0.88 | PDE4A (0.47) | SLC34A1BRD4CREBBPPDE4BACHE | |
| SCHEMBL3037450 | 0.87 | BRD4 (0.45) | SLC34A1BRD4CREBBPPDE4BACHE | |
| SCHEMBL4708332 | 0.86 | PDE4B (0.46) | SLC34A1BRD4CREBBPPDE4BMCHR1 | |
| SCHEMBL4708371 | 0.84 | PDE4B (0.54) | SLC34A1BRD4CREBBPPDE4BMCHR1 | |
| SCHEMBL1652321 | 0.84 | BRD4 (0.43) | SLC34A1BRD4CREBBPPDE4BACHE | |
| SCHEMBL1653014 | 0.83 | PDE4B (0.46) | SLC34A1BRD4CREBBPPDE4BMCHR1 | |
| SCHEMBL4706044 | 0.81 | PDE4B (0.55) | PDE4BACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459453-B2 | Pyridazin-3(2H)-one derivatives as PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-12-02 | — | — | US | disclosed |
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | DAL PIAZ VITTORIO | 2008-10-30 | — | — | US | disclosed |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-03-09 | — | — | US | disclosed |
| EP-1503992-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003097613-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS | ALMIRALL PRODESFARMA SA (ES) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE3A, PDE4B | SLC34A1 1806/4885BRD4 467/4885CREBBP 1695/4885 |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | PDE4A, PDE3A, PDE4B | SLC34A1 1806/4885BRD4 467/4885CREBBP 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.